The candidate vaccine is a novel target identified on the surface of haemorrhagic septicaemia-associated strains of Pasteurella multocida. It has demonstrated robust protection in cattle against lethal challenge with the two serogroups of Pasteurella responsible for HS.

Applying a gender lens to livestock programmes is not an optional add-on, but a strategic necessity. VITAL 2 is a gender-intentional investment, designed to ensure that gender-related barriers and norms are identified and addressed so that women are not excluded from the benefits of ruminant vaccination as markets and delivery systems expand.

Over the years, GALVmed through its partners, has implemented impactful programmes across Africa and South Asia, leading to significant achievements.

If Africa can mobilise the investments needed to eliminate sleeping sickness in people, it can and must show the same commitment to protecting the animals that sustain its economy.

Imagine that over the course of 10 days, 80 per cent of your livelihood is destroyed. This is a reality for millions of small-scale producers in Africa who depend on sheep and goats for income, nutrition and survival, but have to contend with Peste des Petits Ruminants (PPR), a highly contagious disease with a mortality rate of up to 90 per cent.